Professor Louise Emmett
Professor Louise Emmett is the Director of Theranostics and Nuclear medicine at St Vincent's Hospital Sydney. She has been instrumental in developing the radiopharmacy initiative on the St Vincent's Campus and has introduced multiple new radioisotopes for clinical and research purposes. The St Vincent's Theranostics Department is highly published in both PET imaging and radionuclide therapy. Louise is heavily involved in multi-site multidisciplinary trials run across Australia, in addition to undertaking early phase clinical trials on the St Vincent's Campus. She believes in the power of clinical research to optimise treatments and improve lives.
Louise completed medical school at Auckland University (1992), New Zealand and received her FRACP qualification in Sydney, Australia (1999). She undertook a specialty fellowship in Nuclear Cardiology at the University Health Network in Toronto (2000), and completed a Doctorate of Medicine in Nuclear Cardiology through Auckland University in 2014. Since commencing work at St Vincent's Hospital in 2012, her focus has shifted to Theranostics. Happily this shift in focus (mid-life crisis) coincided with the first publication of PSMA imaging in a mouse. Louise is a clinical professor with the University of New South Wales. She has published over 80 original papers in peer reviewed journals in the last 10 years, has received a number of grants for clinical research and has presented at numerous national and international meetings.
Selected publications
See all publications- 2026Nature Cancer10.1038/s43018-026-01140-3
Predictive value of early PSMA upregulation for the response to enzalutamide ± Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.
- 2026European Urology10.1016/j.eururo.2026.03.026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [Lu] Lu-PSMA-617 (ANZUP1901).
- 2026European Urology10.1016/j.eururo.2026.03.001
Prospective Comparison of Copper [Cu]SAR-bisPSMA vs Gallium[Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
- 2026The Lancet. Oncology10.1016/S1470-2045(26)00017-3
[Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
- 2025European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology10.1016/j.ejso.2025.111163
Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the prospective, randomised, phase III Evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial.
